Neuronetics schedules November 4 results for Neuronetics stock

Published on 10/27/2026 at 13:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Neuronetics stock costs EUR 2.01 on October 27, 2026 beside a USD 160.8 million market value. Results follow November 4.

Results date and operating scale

Neuronetics scheduled third-quarter results for November 4, 2026.
Second-quarter revenue reached USD 41.57 million against USD 40.18 million consensus.
Neuronetics stock trades at EUR 2.01 at 1:16 p.m. CEST at Lang & Schwarz on October 27, 2026.
Market capitalization stood at USD 160.8 million on October 26, 2026.

STIM, US64131A1051, Illustration mit AI erstellt.

Neuronetics (ISIN US64131A1051) was priced at EUR 2.01 at Lang & Schwarz on October 27, 2026, at 1:16 p.m. CEST. The medical-device company scheduled its third-quarter 2026 results for November 4, 2026, before the U.S. market opens, as Markets Insider reported on October 21, 2026.

Three dates frame the setup

Neuronetics reported USD 41.57 million of revenue for the second quarter ended June 30, 2026, compared with a USD 40.18 million consensus estimate, according to Benzinga. The comparison shows that quarterly sales exceeded the cited estimate by USD 1.39 million.

On October 21, 2026, the company set November 4, 2026, as the release date and scheduled its conference call for 8:30 a.m. Eastern Time, according to StockTitan. On October 27, 2026, the Lang & Schwarz quote stood at EUR 2.01, providing the latest euro market reference for German investors.

What does the next report test?

The November release will test whether the second-quarter sales pace can continue into the third quarter. Neuronetics combines its NeuroStar transcranial magnetic stimulation system with direct patient care through the Greenbrook clinic network, a model described in the company's investor-relations materials at Neuronetics.

Scale remains the key context

The company says NeuroStar has delivered more than 4.8 million treatment sessions. Barron's lists Neuronetics on Nasdaq, with a USD 160.8 million market value and a USD 0.80 to USD 3.44 52-week range as of October 26, 2026.

Next report sets the near-term test

The November 4 release is the next defined event for the stock, with the scheduled 8:30 a.m. Eastern Time call adding a precise timing marker. The latest reported quarter combines USD 41.57 million in revenue with a USD 3.44 million net loss, while the June 30, 2026 period also showed operating cash flow of negative USD 1.01 million.

The stock was trading at EUR 2.01 at Lang & Schwarz on October 27, 2026, at 1:16 p.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Neuronetics stock.